Tivic Health Systems, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

VBIO$0.54+6.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Shareholders’ Equity

Consolidated Statements of Stockholders’** Equity**

(in thousands except share and per share data)

Mezzanine Equity - Redeemable Convertible Series B Preferred Stock · Mezzanine Equity - Redeemable Convertible Series C Preferred Stock · Preferred Stock · Common Stock · Additional Paid-in Capital · Accumulated Deficit · Total Stockholders' Equity
Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount
Balance as of January 1, 2024	—	$—	—	$—	—	$—	86,241	$—	$41,466	$(37,886)	$3,580
Issuance of common stock for restricted stock award	—	—	—	—	—	—	442	—	—	—	—
Issuance of common stock and warrants, net of issuance costs and warrants issued to placement agents	—	—	—	—	—	—	470,219	1	4,310	—	4,311
Issuance of warrants	—	—	—	—	—	—	—	—	70	—	70
Stock-based compensation expense	—	—	—	—	—	—	—	—	229	—	229
Net loss	—	—	—	—	—	—	—	—	—	(5,655)	(5,655)
Balance as of December 31, 2024	—	$—	—	$—	—	$—	556,902	$1	$46,075	$(43,541)	$2,535
Issuance of common stock and preferred stock, net of issuance costs	—	—	—	—	491	—	519,831	—	4,037	—	4,037
Issuance of common stock for equity line of credit	—	—	—	—	—	—	29,800	—	94	—	94
Issuance of common stock in lieu of fractional shares for stock split	—	—	—	—	—	—	76	—	—	—	—
Settlement of restricted stock units	—	—	—	—	—	—	49,284	—	100	—	100
Issuance of Series B preferred stock and warrants, net of issuance costs and warrants to placement agents	4,900	2,911	—	—	—	—	—	—	1,413	—	1,413
Issuance of Series C preferred stock and warrants, net of issuance costs and warrants to placement agents	—	—	12,000	5,943	—	—	—	—	5,942	—	5,942
Issuance of warrants in connection with senior convertible preferred note payable	—	—	—	—	—	—	—	—	9,404	—	9,404
Issuance of warrants to placement agents as non-cash offering fees	—	—	—	—	—	—	—	—	93	—	93
Exercise of warrants	—	—	—	—	—	—	7,524	—	109	—	109
Conversion of Series A preferred stock into common stock	—	—	—	—	(88)	—	51,504	—	—	—	—
Conversion of Series B preferred stock into common stock	(2,745)	(1,621)	—	—	—	—	1,310,857	1	1,620	—	1,621
Dividends declared on Series B preferred stock	—	89	—	—	—	—	—	—	31	(120)	(89)
Dividends declared on Series C preferred stock	—	—	—	48					—	(48)	(48)
Deemed dividends on purchase warrants for common shares	—	—	—	—	—	—	—	—	10	(10)	—
Stock-based compensation expense	—	—	—	—	—	—	—	—	464	—	464
Net loss	—	—	—	—	—	—	—	—	—	(8,878)	(8,878)
Balance as of December 31, 2025	2,155	$1,379	12,000	$5,991	403	$—	2,525,778	$2	$69,392	$(52,597)	$16,797

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.